Breast cancer

The PBS subsidises lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine for patients with breast cancer.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine under the National Health Act 1953, section 85 and section 100—for the Efficient Funding of Chemotherapy, for patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing lapatinib, pertuzumab, trastuzumab and trastuzumab emtansine.

Applications

Trastuzumab

From 1 October 2019, treatment with trastuzumab is Authority Required (Streamlined) and doesn’t require prior authority approval from us for listed quantities and repeats.

Initial treatment

Apply for authority approval to prescribe initial PBS subsidised lapatinib, pertuzumab and trastuzumab emtansine to treat HER2-positive metastatic breast cancer in writing and either:

All applications must include the completed:

Continuing treatment

To make continuing PBS subsidised pertuzumab and trastuzumab emtansine to treat HER2-positive metastatic breast cancer call the PBS Complex Drugs Programs enquiry line.

Continuing PBS subsidised treatment with lapatinib is Authority Required (Streamlined) and doesn’t need require prior authority approval from us for listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 27 September 2019